Mr. Abel Ang is the Group Chief Executive Officer of Accuron MedTech, where he has overall responsibility for Accuron’s Medical Device activities. Abel has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE:GB), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopedic markets.

 

Prior to Greatbatch, Abel was President, Asia/Pacific for Hill - Rom Inc. a US$1.7B revenue medical devices company (NYSE: HRC) where he was responsible for leading, developing and implementing the strategy to expand Hill - Rom’s presence in the Asia/Pacific markets. He formerly served as the Chief Technology Officer for Hill - Rom for 3 years. In that role, he had overall responsibility for Hill - Rom’s global R&D operations which are distributed across sites in the U.S., Mexico, France, and Singapore. At Hill - Rom, he also held the positions of Vice - President and General Manager of Hill - Rom’s US$420MM Global Surfaces and Therapy Business Unit; and Vice - President for International Business and Technology Development. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board’s (EDB) Biomedical Division.

 

Abel sits on the Board of Economic Development Innovations Singapore, a privately - held company headquartered in Singapore with offices in Germany and the US. With expertise honed in conceiving and managing townships in India, Vietnam, China, and Indonesia, EDIS’ core business is in investing, managing and developing integrated cities globally. Ang also sits on the Board of Exploit Technologies which provides access to Singapore's largest pool of intellectual property and knowledge generated by over 2,000 researchers at A*STAR's research institutes. In addition, he sits on the Boards of the following Accuron Medical Device Operating companies: Dornier Medizintechnik, Veredus Pte Ltd, and Advanced Materials Technologies (AMT) Pte Ltd.

 

Abel is an Adjunct Associate Professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programs. Abel has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School’s Advanced Management Program in 2012.